title: Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons.
abstract: BACKGROUND
  One of the goals of the National HIV/AIDS Strategy (NHAS) is to increase the proportion of HIV-infected individuals linked to care within 3 months of diagnosis (early linkage) from 65% to 85%. Earlier access to care, and eventually, to treatment, increases life expectancy and quality of life for HIV-infected persons. However, longer treatment is also associated with higher costs, especially for antiretroviral drugs. We evaluated the cost effectiveness of achieving the NHAS goal and estimated the maximum cost that HIV programs could spend on linkage to care and remain cost effective.
  
  
  METHODS
  We used the Progression and Transmission of HIV/AIDS model to estimate the effects on life measures and costs associated with increasing early linkage to care from 65% to 85%. We estimated an incremental cost-effectiveness ratio as the additional cost required to reach the target divided by the quality-adjusted life years (QALYs) gained and assumed that programs costing $100,000 or less per QALY gained are cost effective.
  
  
  RESULTS
  Achieving the NHAS linkage-to-care goal increased life expectancy by 0.4 years and delayed the onset of AIDS by 1.2 years on average for every HIV-diagnosed person. Increasing early linkage to care cost an extra $62,200 per QALY gained, considering only benefits to index persons. The maximum that could be cost effectively spent on early linkage-to-care interventions was approximately $5100 per HIV-diagnosed person.
  
  
  CONCLUSIONS
  Considerable investment can be cost effectively made to achieve the NHAS goal on early linkage to care.
authors.affiliation: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS E-48, Atlanta, GA 30333, USA. kiu0@cdc.gov
authors.forename: Chaitra
authors.initials: C
authors.lastname: Gopalappa
authors.forename: Paul G
authors.initials: PG
authors.lastname: Farnham
authors.forename: Angela B
authors.initials: AB
authors.lastname: Hutchinson
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Sansom
mesh_terms: D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D006801:Humans; D008017:Life Expectancy / Q000639:trends; D015233:Models, Statistical; D011788:Quality of Life; D014481:United States / Q000453:epidemiology